Premium
Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism
Author(s) -
Nutt John G.,
Gunzler Steven A.,
Kirchhoff Trish,
Hogarth Penelope,
Weaver Jerry L.,
Krams Michael,
Jamerson Brenda,
Menniti Frank S.,
Landen Jaren W.
Publication year - 2008
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22169
Subject(s) - dyskinesia , parkinsonism , glutamate receptor , antagonist , levodopa , nmda receptor , anesthesia , placebo , medicine , pharmacology , adverse effect , psychology , parkinson's disease , disease , receptor , alternative medicine , pathology
Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double‐blind, placebo‐controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP‐101,606, on the response to 2‐hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP‐101,606 reduced the maximum severity of levodopa‐induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP‐101,606 was associated with a dose‐related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects. © 2008 Movement Disorder Society